Exploring Analyst Estimates for Guardant Health (GH) Q4 Earnings, Beyond Revenue and EPS

The upcoming report from Guardant Health (GH) is expected to reveal quarterly loss of $0.50 per share, indicating an increase of 68.4% compared to the year-ago period. Analysts forecast revenues of $199.86 million, representing an increase of 28.9% year over year.The current level reflects an upward revision of 7.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.That said, let's delve into the average estimates of some Guardant Health metrics that Wall Street analysts commonly model and monitor.Analysts predict that the 'Revenue- Development services and other' will reach $13.14 million. The estimate indicates a change of +2.1% from the prior-year quarter.Based on the collective assessment of analysts, 'Revenue- Precision oncology testing' should arrive at $171.76 million. The estimate indicates a year-over-year change of +20.8%.It is projected by analysts that the 'Total tests performed (clinical & biopharmaceutical customers)' will reach 55,415. Compared to the present estimate, the company reported 55,900 in the same quarter last year.View all Key Company Metrics for Guardant Health here>>>Guardant Health shares have witnessed a change of +31.3% in the past month, in contrast to the Zacks S&P 500 composite's +4.7% move. With a Zacks Rank #2 (Buy), GH is expected outperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Guardant Health, Inc. (GH): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks